Inovio Pharmaceuticals Announces Results Of Phase 1 Clinical Trial Of Coronavirus Vaccine Candidate


Tuesday morning, Inovio Pharmaceuticals (NASDAQ: INO) has released preliminary data from a phase 1 clinical trial for INO-4800, its experimental vaccine against SARS-CoV-2, the coronavirus that causes COVID-19. This trial initially recruited 40 participants aged 18 to 50, but was later modified to include older participants.

As an early stage trial, the study is only looking for data on the safety of INO-4800 and its immunogenicity, that is, its ability to trigger the desired immune response in the body. (Note that three of the trial participants were positive for COVID-19 at the start of the study, indicating that they had contracted the virus before being enrolled in the study, and one left the trial for non-clinical reasons.)

Intermediate data from the trial revealed no serious safety concerns associated with the vaccine – it was “generally safe and well tolerated”. However, the participants experienced redness on the skin where the vaccine was administered. Importantly, 94% of them demonstrated an immune response six weeks after receiving the vaccine. Specifically, Inovio said that its potential vaccine had “the ability to generate balanced immune responses in antibodies and T cells.” (T cells are white blood cells that bind to and kill infected cells.) Biotechnology plans to start a phase 2/3 clinical trial for INO-4800 later this summer, pending regulatory approval.

Image source: Getty Images.

Other developments

Inovio also announced that INO-4800 has been selected for a study under the auspices of the US Government’s Operation Warp Speed, an initiative dedicated to supporting the rapid development of SARS-CoV-2 vaccines. INO-4800, along with other candidate vaccines, will be tested in a challenge study in non-human primates in which inoculated animals are deliberately exposed to the coronavirus.

It should also be noted that Inovio recently won a $ 71 million contract from the Department of Defense, some of which will be used to increase the manufacturing of its Cellectra 3PSP smart devices, and the rest to purchase a large quantity of Cellectra devices. 2000 of Inovio. These two portable injection systems are used to deliver DNA vaccines like INO-4800 more effectively, using electrical pulses to allow vaccines to enter cells of the recipient’s skin directly.


Please enter your comment!
Please enter your name here